Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.

BACKGROUND: We examined the strategy of T-cell depletion of HLA-identical sibling grafts for the prevention of GvHD, as well as disease control and overall survival. PATIENTS AND METHODS: The myeloablative conditioning was radiation based. The source of stem cells was BM in 62, and cytokine-mobiliz...

Bibliográfalaš dieđut
Váldodahkkit:	Novitzky, N, Thomas, V, Hale, G, Waldmann, H
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2004

Geahča maid

Addition of cyclosporin post transplantation decreases GvHD without enhancing the adverse effect of T-cell depletion with CAMPATH-1H "in the bag": The cape town experience
Dahkki: Novitzky, N, et al.
Almmustuhtton: (2003)

T-cell depletion of stem cell grafts with campath-1H "in the bag" followed by cyclosporin immunosuppression remains a cost effective strategy in transplantation
Dahkki: Novitzky, N, et al.
Almmustuhtton: (2004)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
Dahkki: Fibbe, W, et al.
Almmustuhtton: (1993)

CAMPATH-1 antibodies in stem-cell transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (2001)

T-cell depletion of bone marrow grafts with Campath 1 ex vivo prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation
Dahkki: Novitzky, N, et al.
Almmustuhtton: (1997)

Ex vivo T-cell depletion of bone marrow grafts with campath 1 prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation.
Dahkki: Novitzky, N, et al.
Almmustuhtton: (1997)

Specificity of monoclonal antibody Campath-1.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Dahkki: Hale, G, et al.
Almmustuhtton: (2002)

Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect.
Dahkki: Novitzky, N, et al.
Almmustuhtton: (1999)

CAMPATH: from concept to clinic.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (2005)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
Dahkki: Dyer, M, et al.
Almmustuhtton: (1989)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
Dahkki: Dyer, M, et al.
Almmustuhtton: (1990)

Availability of Campath-1 antibodies for bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1994)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
Dahkki: Potter, M, et al.
Almmustuhtton: (2000)

CAMPATH-1H in inflammatory arthritis.
Dahkki: Watts, R, et al.
Almmustuhtton: (1993)

The CAMPATH-1 antigen (CDw52).
Dahkki: Hale, G, et al.
Almmustuhtton: (1990)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
Dahkki: Hale, G, et al.
Almmustuhtton: (1996)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (1987)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Dahkki: Williams, R, et al.
Almmustuhtton: (2000)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
Dahkki: Lim, S, et al.
Almmustuhtton: (1993)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Dahkki: Hale, G, et al.
Almmustuhtton: (1994)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
Dahkki: Xia, M, et al.
Almmustuhtton: (1993)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
Dahkki: Watts, R, et al.
Almmustuhtton: (1992)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
Dahkki: Lim, S, et al.
Almmustuhtton: (1993)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
Dahkki: Dyer, M, et al.
Almmustuhtton: (1989)

Campath-1H therapy in refractory ocular inflammatory disease.
Dahkki: Dick, A, et al.
Almmustuhtton: (2000)

CAMPATH-IH in multiple sclerosis.
Dahkki: Moreau, T, et al.
Almmustuhtton: (1996)

A personal history of the CAMPATH-1H antibody.
Dahkki: Waldmann, H
Almmustuhtton: (2002)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
Dahkki: Killick, S, et al.
Almmustuhtton: (1997)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
Dahkki: Friend, P, et al.
Almmustuhtton: (1988)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
Dahkki: Isaacs, J, et al.
Almmustuhtton: (1996)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
Dahkki: Friend, P, et al.
Almmustuhtton: (1991)

In vivo 'purging' of residual disease in CLL with Campath-1H.
Dahkki: Dyer, M, et al.
Almmustuhtton: (1997)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2004)

T-CELL DEPLETION BY EXPOSURE TO CAMPATH-1G IN-VITRO PREVENTS GRAFT-VERSUS-HOST DISEASE
Dahkki: Jacobs, P, et al.
Almmustuhtton: (1994)

CAMPATH-1 FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT-REJECTION - SUMMARY OF RESULTS FROM A MULTI-CENTRE STUDY
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
Dahkki: Willis, F, et al.
Almmustuhtton: (2001)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
Dahkki: Naparstek, E, et al.
Almmustuhtton: (1999)